2022 World Conference on Lung Cancer (ePosters)-EP08.02-173. Treatment Patterns and Outcomes Among Patients With EGFR-mutant Advanced NSCLC in the Frontline and Post-Osimertinib Settings

EP08.02-173. Treatment Patterns and Outcomes Among Patients With EGFR-mutant Advanced NSCLC in the Frontline and Post-Osimertinib Settings

Back to course

Pdf Summary

This document is a summary of a study presented at the World Conference on Lung Cancer (WCLC) regarding treatment patterns and outcomes among patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC). The study aimed to characterize real-world treatment patterns and outcomes in both the frontline and post-osimertinib settings.<br /><br />The study utilized the ConcertAI Patient360 NSCLC database, which aggregates real-world data from electronic medical records across 100 US oncology practices. The data included patients from 31 US states and were manually curated by a team of nurse practitioners.<br /><br />The study population consisted of patients aged 18 years or older with confirmed diagnosis of advanced/metastatic NSCLC and a common EGFR mutation (exon 19 deletions or exon 21 L858R). The treatment patterns and outcomes were assessed in three cohorts based on the lines of therapy received.<br /><br />The results showed that in the frontline setting (Cohort 1), osimertinib alone or in combination was the most common therapy, followed by other tyrosine kinase inhibitor (TKI) regimens. In the post-osimertinib setting (Cohort 2), platinum chemotherapy and osimertinib retreatment were the main treatment options. In the third cohort, non-platinum-based chemotherapy or immunotherapy monotherapy were used, and some patients were re-exposed to osimertinib.<br /><br />The study also analyzed the outcomes in terms of progression-free survival, time to treatment discontinuation, and time to next treatment across the three cohorts. The findings demonstrated reduced duration of treatment and survival as patients progressed through their treatment journeys.<br /><br />In conclusion, the study suggests the need for newer and more effective therapeutics after osimertinib treatment, as reflected by the heterogeneity in treatments received post-osimertinib and post-platinum chemotherapy. These findings provide valuable insights into the real-world treatment patterns and outcomes for patients with EGFR-mutant advanced NSCLC.

Asset Subtitle

Joshua Sabari

Meta Tag

Speaker Joshua Sabari

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

World Conference on Lung Cancer

epidermal growth factor receptor

EGFR-mutant non-small cell lung cancer

treatment patterns

outcomes

frontline setting

post-osimertinib setting

ConcertAI Patient360 NSCLC database

real-world data

lines of therapy